Kala azar in India

Last updated

Kala azar (Visceral leishmaniasis) in India refers to the special circumstances of the disease kala azar as it exists in India. Kala azar is a major health problem in India with an estimated 146,700 new cases per year as of 2012. [1] In the disease a parasite causes sickness after migrating to internal organs such as the liver, spleen and bone marrow. If left untreated the disease almost always results in the death. Signs and symptoms include fever, weight loss, fatigue, anemia, and substantial swelling of the liver and spleen.

Contents

People get the disease from the bites of sandflies which themselves got a parasite from drinking blood of another person infected with the parasite. Globally there are more than 20 different Leishmania parasites which cause the disease and 90 species of sandfly which spread those parasites. [2] In the Indian subcontinent, however, there is only one common species of parasite, Leishmania donovani and only one species of sandfly, Phlebotomus argentipes , which spreads the disease. [3] The form of the disease, the medicine for eliminating the parasite, and insecticide for preventing the insect bite varies by region, and there are recommendations in place for India. [4]

Besides the personal cost, the disease has a great economic cost to the affected communities and India in general. [4]

Types

Kala azar causes various changes in the body Parasites of the tropical diseases Kala-Azar and Oriental So Wellcome V0022616.jpg
Kala azar causes various changes in the body

A 2012 report based on 2004-8 data estimated that the number of new annual cases of kala azar was at least 146,000 in India, 12,000 in Bangladesh, and 3,000 in Nepal. [1] Among all the people the subcontinent carrying infection, 10% have kala azar, 10% have PKDL, and 80% are asymptomatic. [5]

Kala azar

Kala azar, also called visceral leishmaniasis, is a disease in which a parasite migrates to the internal organs such as the liver, spleen (hence "visceral"), and bone marrow. If left untreated, will almost always result in the death of the host. Signs and symptoms include fever, weight loss, fatigue, anemia, and substantial swelling of the liver and spleen.[ citation needed ]

Among people with kala azar, there is variation in the symptoms, and some people can have unusual symptoms. [6]

Asymptomatic kala azar

Asymptomatic kala azar (also called asymptomatic Leishmania infection) occurs when someone has the infection but does not show symptoms. [7]

For every 1 person with kala azar symptoms, 4–17 people may have asymptomatic kala azar. [7] Risk of asymptomatic kala azar is high for anyone in close contact with a person with kala azar. [7] Most people who would test positive for asymptomatic kala azar will clear the infection naturally. [7] Between 1–23% of asymptomatic people will develop kala azar within 1 year. [7]

Post-kala-azar dermal leishmaniasis

Post-kala-azar dermal leishmaniasis (PKDL) is a complication of visceral leishmaniasis (VL); it is characterised by a macular, maculopapular, and nodular rash in a patient who has recovered from VL and who is otherwise well. Despite being called "post kala azar", 29% of cases appear from people who never had kala azar, and who had an asymptomatic infection previously. [7]

Vector

diagram of how kala azar spreads in India Transmission dynamics of visceral leishmaniasis in the Indian subcontinent.png
diagram of how kala azar spreads in India

In various places in the world different sandflies transmit different Leishmania parasites which cause different variations of kala azar. In the Indian subcontinent the particular sandfly is Phlebotomus argentipes and it transmits Leishmania donovani . One part of preventing the disease in India is preventing the insect bite. [3]

A challenge with preventing the insect bite is lack of ecological data and lack of information about the life of the insect. Ecological information which would predict when and where sandflies live include temperature, rain, wind speed, Relative humidity, soil moisture, pH, and total organic carbon. [8] If that information were available, then it would be easier to study when insects bite, how they choose to bite either animals or humans, and where they breed. [8] Knowing about insect life and behavior would increase efficiency and lower cost of public health programmes to prevent kala azar. [8]

Using insecticide treated nets in 90% of the households in districts with kala azar could be an effective part of controlling the spread of disease. [3]

There is no evidence that animals are a major concern for spread of kala azar. [9] Tests of cattle, buffalo, chickens, wild rats, and dogs found little or no infection. [9] There is some evidence that goats could be reservoirs of infection. [9]

Treatment

Kala azar is a community problem and requires individual and community participation in treatment. [4] Treatment starts with healthcare workers seeking people with the disease. [4] There is testing in clinics but also in the field. [4] Preferred treatment is a single injection of liposomal amphotericin B at a clinic on the same day as testing and diagnosis. By doing everything in one visit, people will be able to easily complete treatment. [4] Even after treatment, people may require a follow up including some combination therapy. Some people may require an alternative therapy and other drugs are effective.[ citation needed ]

Miltefosine is the only available oral medication available for VL and PKDL. [10] While the drug works for short term treatment of VL, PKDL would require a longer treatment of more than 28 days with this drug. [10] Miltefosine is not recommended for use as a monotherapy to treat PKDL. [10]

Elimination of disease

The eradication of kala azar in India is achievable and there are favorable circumstances for doing so. [3] Humans are the only reservoir host in this region for the parasite causing the disease. [3] The only way the disease spreads from human to human is by one insect in the region, Phlebotomus argentipes . [3] As of 2009, the disease only existed in 109 districts in India, Bangladesh, and Nepal. [3] The disease is easy to diagnose, even in the field and outside of a clinic. [3] When testing identifies a patient with the condition, then available drugs are completely effective in removing the parasite. [3]

The current goal for eliminating the disease is to have its rate below 1 in 10,000 people by 2020. [11]

One part of the elimination strategy was to reduce sandflies as a vector by giving mosquito nets treated with DDT along with programs for early case detection and treatment. [12] [13]

Challenges

Major challenges in eliminating kala azar is lack of access to health care, planning for drug resistance, the absence of a kala azar vaccine, and the difficulty in controlling the insect spreading the infection. [14] Progress in diagnosis, treatment, and the development of a vaccine is significant and is guiding the elimination planning. [14] A program to eliminate kala azar would only work with strong support from local communities. [14] Public health surveillance is necessary for years to identify cases as soon as possible for treatment and to prevent spread. [14]

Humans with the parasite are reservoirs of infection which could revive the disease even if it seems eliminated. [7] People with asymptomatic kala azar can still spread the disease and so can people who seem cured of kala azar, but who later development PKDL. [7]

Potential great dangers to elimination are drug resistance and pesticide resistance and a need for pharmacovigilance to ensure drug safety for using the medications. [15]

Public health programs

The India National Health Policy, 2002 set a goal to eliminate kala azar by 2010. [16] The Central Government of India started supporting states with case registration in 2003. [17] In 2005 the governments of India, Nepal, and Bangladesh started an initiative with the World Health Organization to collaborate in eliminating kala azar in the region. [18]

India changed the target year to 2015. [16] When the year came there was uncertainty that the goal would be met. [19] In February 2015 the health ministers of India, Bangladesh, and Nepal joined with the health ministers of Thailand and Bhutan to set a new target date to eliminate kala azar by 2017. [20]

History

Upendranath Brahmachari researched kala-azar in Kolkata Scientist Sir Upendra Nath Brahmachari.png
Upendranath Brahmachari researched kala-azar in Kolkata
The miracle of urea stibamine, drawn by Upendranath Brahmachari himself. The death rate is drastically declined from nearly 6300 to 750 within ten years in Assam. Number of Deaths from Kala-Azar in Assam.svg
The miracle of urea stibamine, drawn by Upendranath Brahmachari himself. The death rate is drastically declined from nearly 6300 to 750 within ten years in Assam.

India has long been involved in drug development for kala azar. [21]

William Twining, an East India Company military physician, wrote a modern medical description of kala azar in 1835. [22]

In 1903 William Boog Leishman, a British Army medical officer, reported from Dum Dum near Calcutta identifying parasites which cause kala azar. [23] [24] His report was correct, and scientists gave his name to the parasite Leishmania and to the Western name of the disease, leishmaniasis. [24]

Bengali physician and scientist Upendranath Brahmachari treated, researched, and published about kala-azar until his death in 1946. [25]

India's National Malaria Eradication Programme was using DDT between 1953 and 1964 as the insecticide to prevent malaria. [26] DDT is highly effective was banned for also being toxic to humans and the environment. [26] When India was using DDT, that effort to reduce malaria also killed sandflies and prevented kala azar. [26] [27] After 1964 and the halt of DDT use, kala azar returned, but physicians no longer recognized the disease after its absence. [26]

From about 1960–1975, there were no records of kala azar in the subcontinent. [28] In 1978 in Nepal, people reported the disease. [28] From 1980 the disease spread among many people. [28]

Special populations

Quackery is common enough to be a significant problem in treating the disease. The government seeks to make official clinics accessible, but many people take services from unlicensed medical practitioners. [15] [29]

Men are more likely than women to get kala azar. [30]

Children with kala azar have the same symptoms as adults. [31] Miltefosine is as effective and well tolerated as a treatment in children as adults and can be a first line treatment. [32] 90% of the cases of kala azar are in Bihar, and children there have the burden of 50% of the loss of disability adjusted life years. [31]

HIV-positive people have a greater risk of reinfection of kala azar. [33] [34]

Related Research Articles

<i>Leishmania</i> Genus of parasitic flagellate protist

Leishmania is a parasitic protozoan, a single-celled organism of the genus Leishmania that is responsible for the disease leishmaniasis. They are spread by sandflies of the genus Phlebotomus in the Old World, and of the genus Lutzomyia in the New World. At least 93 sandfly species are proven or probable vectors worldwide. Their primary hosts are vertebrates; Leishmania commonly infects hyraxes, canids, rodents, and humans.

<span class="mw-page-title-main">Leishmaniasis</span> Disease caused by parasites of the Leishmania type

Leishmaniasis is a wide array of clinical manifestations caused by parasites of the Trypanosomatida genus Leishmania. It is generally spread through the bite of phlebotomine sandflies, Phlebotomus and Lutzomyia, and occurs most frequently in the tropics and sub-tropics of Africa, Asia, the Americas, and southern Europe. The disease can present in three main ways: cutaneous, mucocutaneous, or visceral. The cutaneous form presents with skin ulcers, while the mucocutaneous form presents with ulcers of the skin, mouth, and nose. The visceral form starts with skin ulcers and later presents with fever, low red blood cell count, and enlarged spleen and liver.

<span class="mw-page-title-main">Sandfly</span> Name of several types of blood-sucking fly

Sandfly or sand fly is a colloquial name for any species or genus of flying, biting, blood-sucking dipteran (fly) encountered in sandy areas. In the United States, sandfly may refer to certain horse flies that are also known as "greenheads", or to members of the family Ceratopogonidae. The bites usually result in a small, intensely itchy bump or welt, the strength of which intensifies over a period of 5-7 days before dissipating. Moderate relief is achieved with varying success through the application of over the counter products such as Benadryl (ingested) or an analgesic cream such as After Bite. Outside the United States, sandfly may refer to members of the subfamily Phlebotominae within the Psychodidae. Biting midges (Ceratopogonidae) are sometimes called sandflies or no-see-ums. New Zealand sandflies are in the genus of sand fly Austrosimulium, a type of black fly.

<i>Lutzomyia</i> Genus of flies

Lutzomyia is a genus of phlebotomine sand flies consisting of nearly 400 species, at least 33 of which have medical importance as vectors of human disease. Species of the genus Lutzomyia are found only in the New World, distributed in southern areas of the Nearctic and throughout the Neotropical realm. Lutzomyia is one of the two genera of the subfamily Phlebotominae to transmit the Leishmania parasite, with the other being Phlebotomus, found only in the Old World. Lutzomyia sand flies also serve as vectors for the bacterial Carrion's disease and a number of arboviruses.

<i>Phlebotomus</i> Genus of flies

Phlebotomus is a genus of "sand flies" in the Diptera family Psychodidae. In the past, they have sometimes been considered to belong in a separate family, Phlebotomidae, but this alternative classification has not gained wide acceptance.

<span class="mw-page-title-main">Cutaneous leishmaniasis</span> Medical condition

Cutaneous leishmaniasis is the most common form of leishmaniasis affecting humans. It is a skin infection caused by a single-celled parasite that is transmitted by the bite of a phlebotomine sand fly. There are about thirty species of Leishmania that may cause cutaneous leishmaniasis.

<span class="mw-page-title-main">Visceral leishmaniasis</span> Human disease caused by protist parasites

Visceral leishmaniasis (VL), also known as kala-azar or "black fever", is the most severe form of leishmaniasis and, without proper diagnosis and treatment, is associated with high fatality. Leishmaniasis is a disease caused by protozoan parasites of the genus Leishmania.

<span class="mw-page-title-main">Drugs for Neglected Diseases Initiative</span> Non-profit organization

The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness, Chagas disease, malaria, filarial diseases, mycetoma, paediatric HIV, cryptococcal meningitis, hepatitis C, and dengue. DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.

<span class="mw-page-title-main">Miltefosine</span> Phospholipid drug

Miltefosine, sold under the trade name Impavido among others, is a medication mainly used to treat leishmaniasis and free-living amoeba infections such as Naegleria fowleri and Balamuthia mandrillaris. This includes the three forms of leishmaniasis: cutaneous, visceral and mucosal. It may be used with liposomal amphotericin B or paromomycin. It is taken by mouth.

<i>Leishmania major</i> Species of parasitic protist

Leishmania major is a species of parasite found in the genus Leishmania, and is associated with the disease zoonotic cutaneous leishmaniasis. L. major is an intracellular pathogen which infects the macrophages and dendritic cells of the immune system. Though Leishmania species are found on every continent aside from Antarctica, Leishmania major is found only in the Eastern Hemisphere, specifically in Northern Africa, the Middle East, Northwestern China, and Northwestern India.

<span class="mw-page-title-main">Canine leishmaniasis</span> Disease affecting dogs

Canine leishmaniasis (LEESH-ma-NIGH-ah-sis) is a zoonotic disease caused by Leishmania parasites transmitted by the bite of an infected phlebotomine sandfly. Canine leishmaniasis was first identified in Europe in 1903, and in 1940, 40% of all dogs in Rome were determined to be positive for leishmaniasis. Traditionally thought of as a disease only found near the Mediterranean basin, 2008 research claims new findings are evidence that canine leishmaniasis is currently expanding in continental climate areas of northwestern Italy, far from the recognized disease-endemic areas along the Mediterranean coasts. Cases of leishmaniasis began appearing in North America in 2000, and, as of 2008, Leishmania-positive foxhounds have been reported in 22 U.S. states and two Canadian provinces.

<i>Leishmania donovani</i> Species of intracellular parasite

Leishmania donovani is a species of intracellular parasites belonging to the genus Leishmania, a group of haemoflagellate kinetoplastids that cause the disease leishmaniasis. It is a human blood parasite responsible for visceral leishmaniasis or kala-azar, the most severe form of leishmaniasis. It infects the mononuclear phagocyte system including spleen, liver and bone marrow. Infection is transmitted by species of sandfly belonging to the genus Phlebotomus in Old World and Lutzomyia in New World. The species complex it represents is prevalent throughout tropical and temperate regions including Africa, China, India, Nepal, southern Europe, Russia and South America. The species complex is responsible for thousands of deaths every year and has spread to 88 countries, with 350 million people at constant risk of infection and 0.5 million new cases in a year.

<i>Leishmania tropica</i> Species of protozoan parasite

Leishmania tropica is a flagellate parasite and the cause of anthroponotic cutaneous leishmaniasis in humans. This parasite is restricted to Afro-Eurasia and is a common cause of infection in Afghanistan, Iran, Syria, Yemen, Algeria, Morocco, and northern India.

Leishmania braziliensis is a Leishmania species.

<span class="mw-page-title-main">Post-kala-azar dermal leishmaniasis</span>

Post-kala-azar dermal leishmaniasis (PKDL) is a complication of visceral leishmaniasis (VL); it is characterised by a macular, maculopapular, and nodular rash in a patient who has recovered from VL and who is otherwise well. The rash usually starts around the mouth from where it spreads to other parts of the body depending on severity.

<i>Lutzomyia longipalpis</i> Species of fly

Lutzomyia longipalpis is a species complex of sandfly belonging to the family Psychodidae. This species is primarily present in Central and South America, but has also appeared in Mexico. There have been reports of L. longipalpis as far south as Argentina, as they are found in a wide variety of ecological conditions. Both males and females feed on sugars from plants and aphids, but only adult females feed on the blood of other mammals. The species has recently begun appearing in urban areas throughout Brazil, and serves as a key vessel for the propagation of the parasite Leishmania infantum. The presence of these flies appears to be strongly correlated to the presence of domestic chickens in Latin America. The first major urban outbreak of the lethal Visceral leishmanias epidemic was detected in Teresina, Piauí State in the early 1980s following a massive planting of acacias.

Neglected tropical diseases in India are a group of bacterial, parasitic, viral, and fungal infections that are common in low income countries but receive little funding to address them. Neglected tropical diseases are common in India.

<span class="mw-page-title-main">Leishmaniasis vaccine</span> Vaccine against leishmaniasis

A Leishmaniasis vaccine is a vaccine which would prevent leishmaniasis. As of 2017, no vaccine for humans was available. Currently some effective leishmaniasis vaccines for dogs exist.

Phlebotomus argentipes are a species of sandfly in genus Phlebotomus in the Indian subcontinent They are notable as a vector for Leishmania donovani, the parasite which causes leishmaniasis.

Shyam Sundar is an Indian academic and professor at Banaras Hindu University. He works on Infectious Diseases - Leishmaniasis & HIV/AIDS.

References

  1. 1 2 Alvar, Jorge; Vélez, Iván D.; Bern, Caryn; Herrero, Mercé; Desjeux, Philippe; Cano, Jorge; Jannin, Jean; Boer, Margriet den; Kirk, Martyn (31 May 2012). "Leishmaniasis Worldwide and Global Estimates of Its Incidence". PLOS ONE. 7 (5): e35671. Bibcode:2012PLoSO...735671A. doi: 10.1371/journal.pone.0035671 . PMC   3365071 . PMID   22693548.
  2. ↑ World Health Organization (14 March 2019). "Leishmaniasis Fact Sheet". www.who.int. World Health Organization.
  3. 1 2 3 4 5 6 7 8 9 Joshi, AB; Das, ML; Akhter, S; Chowdhury, R; Mondal, D; Kumar, V; Das, P; Kroeger, A; Boelaert, M; Petzold, M (5 October 2009). "Chemical and environmental vector control as a contribution to the elimination of visceral leishmaniasis on the Indian subcontinent: cluster randomized controlled trials in Bangladesh, India and Nepal". BMC Medicine. 7: 54. doi: 10.1186/1741-7015-7-54 . PMC   2763005 . PMID   19804620.
  4. 1 2 3 4 5 6 Regional Office for South-East Asia (2012), Regional strategic framework for elimination of kala-azar from the South-East Asia Region (2011-2015), New Delhi: World Health Organization, hdl:10665/205826
  5. ↑ Le Rutte, Epke A.; Coffeng, Luc E.; Bontje, Daniel M.; Hasker, Epco C.; Ruiz Postigo, José A.; Argaw, Daniel; Boelaert, Marleen C.; De Vlas, Sake J. (2016). "Feasibility of eliminating visceral leishmaniasis from the Indian subcontinent: explorations with a set of deterministic age-structured transmission models". Parasites & Vectors. 9 (1): 24. doi: 10.1186/s13071-016-1292-0 . ISSN   1756-3305. PMC   4717541 . PMID   26787302.
  6. ↑ Thakur, L; Singh, KK; Shanker, V; Negi, A; Jain, A; Matlashewski, G; Jain, M (September 2018). "Atypical leishmaniasis: A global perspective with emphasis on the Indian subcontinent". PLOS Neglected Tropical Diseases. 12 (9): e0006659. doi: 10.1371/journal.pntd.0006659 . PMC   6159859 . PMID   30260957.
  7. 1 2 3 4 5 6 7 8 Hirve, S; Boelaert, M; Matlashewski, G; Mondal, D; Arana, B; Kroeger, A; Olliaro, P (August 2016). "Transmission Dynamics of Visceral Leishmaniasis in the Indian Subcontinent – A Systematic Literature Review". PLOS Neglected Tropical Diseases. 10 (8): e0004896. doi: 10.1371/journal.pntd.0004896 . PMC   4973965 . PMID   27490264.
  8. 1 2 3 Chowdhury, R; Kumar, V; Mondal, D; Das, ML; Das, P; Dash, AP; Kroeger, A (May 2016). "Implication of vector characteristics of Phlebotomus argentipes in the kala-azar elimination programme in the Indian sub-continent". Pathogens and Global Health. 110 (3): 87–96. doi:10.1080/20477724.2016.1180775. PMC   4940889 . PMID   27376500.
  9. 1 2 3 Singh, Niti; Mishra, Jyotsna; Singh, Ram; Singh, Sarman (2013). "Animal Reservoirs of Visceral Leishmaniasis in India". The Journal of Parasitology. 99 (1): 64–67. doi:10.1645/GE-3085.1. ISSN   0022-3395. JSTOR   23355018. PMID   22765517. S2CID   41464582.
  10. 1 2 3 Pijpers, J; den Boer, ML; Essink, DR; Ritmeijer, K (February 2019). "The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis". PLOS Neglected Tropical Diseases. 13 (2): e0007173. doi: 10.1371/journal.pntd.0007173 . PMC   6386412 . PMID   30742620.
  11. ↑ Sundar, S; Singh, OP; Chakravarty, J (November 2018). "Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence". Expert Review of Anti-infective Therapy. 16 (11): 805–812. doi:10.1080/14787210.2018.1532790. PMC   6345646 . PMID   30289007.
  12. ↑ Ostyn, B; Vanlerberghe, V; Picado, A; Dinesh, DS; Sundar, S; Chappuis, F; Rijal, S; Dujardin, JC; Coosemans, M; Boelaert, M; Davies, C (August 2008). "Vector control by insecticide-treated nets in the fight against visceral leishmaniasis in the Indian subcontinent, what is the evidence?". Tropical Medicine & International Health. 13 (8): 1073–85. doi: 10.1111/j.1365-3156.2008.02110.x . PMID   18564350. S2CID   2471946.
  13. ↑ Rijal, Suman; Sundar, Shyam; Mondal, Dinesh; Das, Pradeep; Alvar, Jorge; Boelaert, Marleen (22 January 2019). "Eliminating visceral leishmaniasis in South Asia: the road ahead". BMJ. 364: k5224. doi:10.1136/bmj.k5224. PMC   6340338 . PMID   30670453.
  14. 1 2 3 4 Singh, OP; Hasker, E; Boelaert, M; Sundar, S (December 2016). "Elimination of visceral leishmaniasis on the Indian subcontinent". The Lancet. Infectious Diseases. 16 (12): e304–e309. doi:10.1016/S1473-3099(16)30140-2. PMC   5177523 . PMID   27692643.
  15. 1 2 Bhattacharya, SK; Dash, AP (April 2017). "Elimination of Kala-Azar from the Southeast Asia Region". The American Journal of Tropical Medicine and Hygiene. 96 (4): 802–804. doi:10.4269/ajtmh.16-0279. PMC   5392624 . PMID   28115678.
  16. 1 2 Thakur, C. P. (1 December 2016). "Is elimination of kala-azar feasible by 2017?". Indian Journal of Medical Research. 144 (6): 799–802. doi: 10.4103/ijmr.IJMR_335_16 . ISSN   0971-5916. PMC   5433271 . PMID   28474615.
  17. ↑ Dhillon, GP; Sharma, SN; Nair, B (October 2008). "Kala-azar elimination programme in India". Journal of the Indian Medical Association. 106 (10): 664, 666–8. PMID   19552101.
  18. ↑ Regional Office for South-East Asia (2005), Regional strategic framework for elimination of kala azar from the South-East Asia Region (2005–2015), New Delhi: World Health Organization, hdl:10665/205825
  19. ↑ Cousins, Sophie (28 July 2015). "India unlikely to meet goal of eliminating kala-azar by 2015, say experts". BMJ. 351: h4117. doi:10.1136/bmj.h4117. PMID   26220177. S2CID   39380201.
  20. ↑ World Health Organization (14 July 2015), Postigo, J. Ruiz (ed.), Kala-Azar elimination programme – Report of a WHO consultation of partners, Geneva, Switzerland, 10–11 February 2015, Geneva: World Health Organization, ISBN   978-92-4-150949-7, archived from the original on March 29, 2017
  21. ↑ Alves, F; Bilbe, G; Blesson, S; Goyal, V; Monnerat, S; Mowbray, C; Muthoni Ouattara, G; Pécoul, B; Rijal, S; Rode, J; Solomos, A; Strub-Wourgaft, N; Wasunna, M; Wells, S; Zijlstra, EE; Arana, B; Alvar, J (October 2018). "Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives". Clinical Microbiology Reviews. 31 (4). doi:10.1128/CMR.00048-18. PMC   6148188 . PMID   30158301.
  22. ↑ Gupta, PCS (May 1947). "History of Kala-Azar in India". The Indian Medical Gazette. 82 (5): 281–286. PMC   5196405 . PMID   29015274.
  23. ↑ Leishman, WB (1903). "On the possibility of the occurrence of trypanosomiasis in India. 1903". The Indian Journal of Medical Research. 123 (3): 1252–4, discussion 79. PMID   16789342.
  24. 1 2 Steverding, D (15 February 2017). "The history of leishmaniasis". Parasites & Vectors. 10 (1): 82. doi: 10.1186/s13071-017-2028-5 . PMC   5312593 . PMID   28202044.
  25. ↑ Singh, Rajinder; Roy, Syamal (1 March 2019). "U N Brahmachari: Scientific Achievements and Nomination for the Nobel Prize and the Fellowship of the Royal Society of London". Indian Journal of History of Science. 54 (1). doi:10.16943/ijhs/2019/v54i1/49596.
  26. 1 2 3 4 Rao, Menaka (27 October 2016). "India has been talking about defeating kala azar since 1947 – and now has a good chance of doing so". Scroll.in .
  27. ↑ Bublitz, DC; Poché, RM; Garlapati, R (June 2016). "Measures to Control Phlebotomus argentipes and Visceral Leishmaniasis in India". Journal of Arthropod-borne Diseases. 10 (2): 113–26. PMC   4906751 . PMID   27308270.
  28. 1 2 3 Joshi, AB; Banjara, MR; Pokhrel, S; Jimba, M; Singhasivanon, P; Ashford, RW (2006). "Elimination of visceral leishmaniasis in Nepal: pipe-dreams and possibilities". Kathmandu University Medical Journal (KUMJ). 4 (4): 488–96. PMID   18603960.
  29. ↑ Boettcher, Jan P; Siwakoti, Yubaraj; Milojkovic, Ana; Siddiqui, Niyamat A; Gurung, Chitra K; Rijal, Suman; Das, Pradeep; Kroeger, Axel; Banjara, Megha R (6 February 2015). "Visceral leishmaniasis diagnosis and reporting delays as an obstacle to timely response actions in Nepal and India". BMC Infectious Diseases. 15 (1): 43. doi: 10.1186/s12879-015-0767-5 . PMC   4335691 . PMID   25656298.
  30. ↑ Cloots, K; Burza, S; Malaviya, P; Hasker, E; Kansal, S; Mollett, G; Chakravarty, J; Roy, N; Lal, BK; Rijal, S; Sundar, S; Boelaert, M (29 January 2020). "Male predominance in reported Visceral Leishmaniasis cases: Nature or nurture? A comparison of population-based with health facility-reported data". PLOS Neglected Tropical Diseases. 14 (1): e0007995. doi: 10.1371/journal.pntd.0007995 . PMC   7010295 . PMID   31995564.
  31. 1 2 Bhattacharya, S.K.; Sur, Dipika; Karbwang, Juntra (March 2006). "Childhood visceral leishmaniasis" (PDF). Indian Journal of Medical Research. 123 (123): 353–356. PMID   16778316.
  32. ↑ Bhattacharya, SK; Jha, TK; Sundar, S; Thakur, CP; Engel, J; Sindermann, H; Junge, K; Karbwang, J; Bryceson, AD; Berman, JD (15 January 2004). "Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India". Clinical Infectious Diseases. 38 (2): 217–21. doi: 10.1086/380638 . PMID   14699453.
  33. ↑ Cota, Gláucia F.; de Sousa, Marcos R.; Rabello, Ana; Jaffe, Charles L. (7 June 2011). "Predictors of Visceral Leishmaniasis Relapse in HIV-Infected Patients: A Systematic Review". PLOS Neglected Tropical Diseases. 5 (6): e1153. doi: 10.1371/journal.pntd.0001153 . PMC   3110161 . PMID   21666786.
  34. ↑ Singh, Sarman (December 2014). "Changing trends in the epidemiology, clinical presentation, and diagnosis of Leishmania–HIV co-infection in India". International Journal of Infectious Diseases. 29: 103–112. doi: 10.1016/j.ijid.2014.07.011 . PMID   25449244.

Further consideration

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.